Organisations › Biological

OraSure Technologies

Bethlehem, United StatesFounded 1987Industry

OraSure Technologies makes sample collection and rapid diagnostic products including Ebola testing. CBRNE-relevant work is a minor part of its offering according to its website.

What it does

rapid diagnostic testsrapid testsample collection

Threats covered

Ebola/filoviruses
Categories

Profile

OraSure Technologies is a Bethlehem, Pennsylvania diagnostics company, founded in 1987 as SolarCare and publicly traded on Nasdaq under OSUR. Its first-generation OraQuick Ebola Rapid Antigen Test received US Food and Drug Administration De Novo authorisation in 2019.

More profile

In July 2026 the FDA granted Emergency Use Authorization, number EUA260001, for the second-generation OraQuick Ebola 2.0 Rapid Antigen Test, which detects all four Ebola viruses that cause human disease and is restricted to authorised high-complexity laboratories. A local business report covered the authorisation.

Its annual report for 2025 is on the SEC register. Ebola testing is one line within a business that is mostly infectious disease and sample collection diagnostics.

Contract values were not read.

Ownership

Publicly listed on Nasdaq (OSUR)

Parent: none (publicly listed) (checked)

Sources (5)
Not verified or not found
  • BARDA or government contract values: not read.
  • Statement that the business is mostly infectious disease and sample collection: not cited in these sources.
Questions

What does OraSure Technologies do?

OraSure Technologies makes sample collection and rapid diagnostic products including Ebola testing. CBRNE-relevant work is a minor part of its offering according to its website.

Where is OraSure Technologies based?

HQ (as found): Bethlehem. HQ country: US.

Who owns OraSure Technologies?

Publicly listed on Nasdaq (OSUR). Parent: none (publicly listed) (checked)

Profiles are compiled from public sources and sampled-checked, not fully audited. Last verified 17 October 2026. Report a correction